focus -WSS

focus

author：fashion 2025-09-28 21:11:43 - browse：7848

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Illinois Supreme Court finds assault weapons ban constitutional

WSS

#NeedHerScience: shining a light on gender disparities in medicine

Patients, digital health players weigh in on FTC's data privacy plan

Gene therapy has helped boys walk. Can scientists keep it that way?

The story of mRNA: From a loose idea to a tool that may help curb Covid

Montana youths win climate lawsuit against state for promoting fossil fuels

Biogen’s boardroom scandal saddles CEO with first crisis

focus

focus

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Death of patient in Alzheimer’s trial raises question of possible risks

What does generative AI mean for health care? We asked experts

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Supreme Court strikes down use of affirmative action

Montana youths win climate lawsuit against state for promoting fossil fuels

How one medical school became remarkably diverse

Dozens dead from Maui wildfires: What we know about the victims

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Novo Nordisk touts Wegovy study, but still struggling with supply

hotspot

Illumina slashes 2023 revenue projections yet again

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Illinois Supreme Court finds assault weapons ban constitutional

Megan Rapinoe shares emotional post following US Women's World Cup exit

Idaho college killings prosecutors challenge defense's grand jury claims

explore

explore

hotspot

leisure time